Tilting at windmills
Sometimes I wonder when we are faced with particularly difficult challenges in oncology – there are certainly plenty of these to go around – if people give up before they start and consider certain endeavours far too difficult and thus any emergent approaches are considered tilting at windmills.
What if we could isolate and define the problem more specifically, thereby identifying where new targets might lie and then go about designing ways to tackle them?
When we do this the problem at hand is much more specific and less amorphous.
Here, we highlight and explore a key topic likely to be lurking in many abstracts over the next week across both hematologic malignancies and solid tumours alike… it’s an important subject many will ignore at their peril.
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
